UNSPSC 51311606: Mepyramine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular structure C17H23N3O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5T3R4P0I14 chemically known as 1,2-ethanediamine, n1-((4-methoxyphenyl)methyl)-n2,n2-dimethyl-n1-2-pyridinyl-, hydrochloride (1:1), but more commonly known as mepyramine hydrochloride, which bears US NIH Compound Identifier 80139. European Medicines Agency schedules Mepyramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14515MIG.

Most nations, for tariff and trade purposes, schedule mepyramine hydrochloride under HS 29333999. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2CCCCN2.CL.

UNSPSC 51311606 Mepyramine hydrochloride is a Commodity code that in practice encompasses pharmaceutical products, including antihistamines and related pharmaceutical compounds, procured by state and local health and human services agencies to support community health initiatives, emergency response programs, and pharmacy benefit management. Recent solicitations show state and local bodies acquiring naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) requirements, and established wholesaler relationships. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission represent the current buyer mix, alongside the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers pharmaceutical procurements on behalf of participating state and local government facilities.

Recent activity spans Florida and Minnesota, with the Texas HHS Commission conducting early-stage market research. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026. The Minnesota Department of Administration's Office of State Procurement issued MMCAP's RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers and maintain cGMP certification and DSCSA compliance. Texas HHS issued RFI HHS0017013 on April 3, 2026, as an exploratory procurement mechanism to gather vendor capabilities regarding direct-to-manufacturer prescription programs, with no formal budget or award value specified at the information-gathering stage.